(HealthDay)—A four-month rifapentine-based regimen containing moxifloxacin is noninferior to a standard six-month regimen for treatment of tuberculosis, according to a study published in the May 6 […]
German firm BioNTech said Thursday that patent protection for COVID-19 vaccines is not holding back production or supply of the jabs that it developed with Pfizer.
(HealthDay)—In two real-world studies, Pfizer’s COVID-19 vaccine appears to be standing up well against the challenges posed by more contagious coronavirus variants from Britain and South […]
The global spread of COVID-19 has raised serious concern for patients with chronic disease. A correlation has been identified between the severity of COVID-19 and a […]